FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 849 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Experts Urge to Remove Care Inequalities for Adolescents and Young Adults... April 8, 2021 EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Moxetumomab... December 21, 2020 Group Dressed as Breasts Gathers to Protest Facebook’s Censorship of Areola... September 2, 2021 EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab August 11, 2022 Load more HOT NEWS 10 Tips for National Cancer Prevention Month FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland Company Gives Cancer Patient a New HVAC System After Treatment and...
